Cargando…
Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge
African swine fever (ASF) is a contagious viral disease of suids that induces high mortality in domestic pigs and wild boars. Given the current spread of ASF, the development of a vaccine is a priority. During an attempt to inactivate the Georgia 2007/1 strain via heat treatment, we fortuitously gen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784117/ https://www.ncbi.nlm.nih.gov/pubmed/36560781 http://dx.doi.org/10.3390/v14122777 |
_version_ | 1784857733945622528 |
---|---|
author | Bourry, Olivier Hutet, Evelyne Le Dimna, Mireille Lucas, Pierrick Blanchard, Yannick Chastagner, Amélie Paboeuf, Frédéric Le Potier, Marie-Frédérique |
author_facet | Bourry, Olivier Hutet, Evelyne Le Dimna, Mireille Lucas, Pierrick Blanchard, Yannick Chastagner, Amélie Paboeuf, Frédéric Le Potier, Marie-Frédérique |
author_sort | Bourry, Olivier |
collection | PubMed |
description | African swine fever (ASF) is a contagious viral disease of suids that induces high mortality in domestic pigs and wild boars. Given the current spread of ASF, the development of a vaccine is a priority. During an attempt to inactivate the Georgia 2007/1 strain via heat treatment, we fortuitously generated an attenuated strain called ASFV-989. Compared to Georgia, the ASFV-989 strain genome has a deletion of 7458 nucleotides located in the 5′-end encoding region of MGF 505/360, which allowed for developing a DIVA PCR system. In vitro, in porcine alveolar macrophages, the replication kinetics of the ASFV-989 and Georgia strains were identical. In vivo, specific-pathogen-free (SPF) pigs inoculated with the ASFV-989 strain, either intramuscularly or oronasally, exhibited transient hyperthermia and slightly decreased growth performance. Animals immunized with the ASFV-989 strain showed viremia 100 to 1000 times lower than those inoculated with the Georgia strain and developed a rapid antibody and cell-mediated response. In ASFV-989-immunized pigs challenged 2 or 4 weeks later with the Georgia strain, no symptoms were recorded and no viremia for the challenge strain was detected. These results show that the ASFV-989 strain is a promising non-GMO vaccine candidate that is usable either intramuscularly or oronasally. |
format | Online Article Text |
id | pubmed-9784117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97841172022-12-24 Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge Bourry, Olivier Hutet, Evelyne Le Dimna, Mireille Lucas, Pierrick Blanchard, Yannick Chastagner, Amélie Paboeuf, Frédéric Le Potier, Marie-Frédérique Viruses Article African swine fever (ASF) is a contagious viral disease of suids that induces high mortality in domestic pigs and wild boars. Given the current spread of ASF, the development of a vaccine is a priority. During an attempt to inactivate the Georgia 2007/1 strain via heat treatment, we fortuitously generated an attenuated strain called ASFV-989. Compared to Georgia, the ASFV-989 strain genome has a deletion of 7458 nucleotides located in the 5′-end encoding region of MGF 505/360, which allowed for developing a DIVA PCR system. In vitro, in porcine alveolar macrophages, the replication kinetics of the ASFV-989 and Georgia strains were identical. In vivo, specific-pathogen-free (SPF) pigs inoculated with the ASFV-989 strain, either intramuscularly or oronasally, exhibited transient hyperthermia and slightly decreased growth performance. Animals immunized with the ASFV-989 strain showed viremia 100 to 1000 times lower than those inoculated with the Georgia strain and developed a rapid antibody and cell-mediated response. In ASFV-989-immunized pigs challenged 2 or 4 weeks later with the Georgia strain, no symptoms were recorded and no viremia for the challenge strain was detected. These results show that the ASFV-989 strain is a promising non-GMO vaccine candidate that is usable either intramuscularly or oronasally. MDPI 2022-12-13 /pmc/articles/PMC9784117/ /pubmed/36560781 http://dx.doi.org/10.3390/v14122777 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bourry, Olivier Hutet, Evelyne Le Dimna, Mireille Lucas, Pierrick Blanchard, Yannick Chastagner, Amélie Paboeuf, Frédéric Le Potier, Marie-Frédérique Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge |
title | Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge |
title_full | Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge |
title_fullStr | Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge |
title_full_unstemmed | Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge |
title_short | Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge |
title_sort | oronasal or intramuscular immunization with a thermo-attenuated asfv strain provides full clinical protection against georgia 2007/1 challenge |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784117/ https://www.ncbi.nlm.nih.gov/pubmed/36560781 http://dx.doi.org/10.3390/v14122777 |
work_keys_str_mv | AT bourryolivier oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge AT hutetevelyne oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge AT ledimnamireille oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge AT lucaspierrick oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge AT blanchardyannick oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge AT chastagneramelie oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge AT paboeuffrederic oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge AT lepotiermariefrederique oronasalorintramuscularimmunizationwithathermoattenuatedasfvstrainprovidesfullclinicalprotectionagainstgeorgia20071challenge |